DIFFUSE MACULAR OEDEMA

Intravitreal triamcinolone acetonide or bevacizumab produce better short-term results than grid laser in the treatment of diffuse macular oedema but all three treatments produce similar results at one year, a comparative study suggests. The study, which involved 126 eyes, showed that eyes receiving intravitreal bevacizumab or triamcinolone had higher rates of anatomical and functional success at six months than did eyes that underwent grid laser treatment (p < 0.05 for both). However, by one year there was no significant difference between the groups in terms of visual stabilisation

(Sobaci et al, Ophthalmologica 2012; 227: 95-99).